Fusion Pharmaceuticals has dosed the first subject in the Phase I/II clinical trial of [225Ac]-FPI-1966 (FPI-1966) in advanced solid tumours expressing fibroblast growth factor receptor three (FGFR3) patients.
The multicentre, open-label trial will analyse the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics of FPI-1966 in FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumour patients.
Go deeper with GlobalData
It has a three + three dose escalation design to assess various ascending doses of FPI-1966.
To determine the effect of pre-dosing on tumour uptake and pharmacokinetics, the first cohort will have sub-groups in which several dosages of non-radiolabeled vofatamab (cold antibody) will be assessed.
Subjects will receive FPI-1967, an imaging analogue of FPI-1966, and people whose imaging meet the predefined tumour uptake will be given FPI-1966.
See Also:
The Phase II segment will have two tumour-specific cohorts and one basket cohort.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAfter initial experience with subject screening through FPI-1967 imaging for predicting the pace of participant enrolment, the company intends to offer guidance on timing for the initial pharmacokinetic, imaging and safety data.
FPI-1966 is a targeted alpha therapy and can act on and offer an alpha-emitting medical isotope, actinium-225, to cancer cells that express FGFR3.
Leveraging the Fast-Clear linker of the company, FPI-1966 connects to a human monoclonal antibody targeting FGFR3, vofatamab, with actinium-225.
Fusion Pharmaceuticals CEO John Valliant said: “This study will evaluate FPI-1966 in patients with solid tumours expressing FGFR3, a validated cancer target found in multiple tumour types with substantial unmet need, notably bladder, ovarian, and head and neck cancers.
“FPI-1966, and the growing number of TATs in our pipeline, are designed as next-generation antibody-drug conjugates [ADCs] in that they leverage the potency of actinium-225 and alpha particle radiation in place of chemical toxins to selectively eradicate cancer cells.”
The company nominated the first targeted alpha therapy (TAT) candidate under a partnership agreement with AstraZeneca to begin Phase I trials.
